Suchergebnisse - Yarur, Andres

Therapeutic Drug Monitoring in Perianal Fistulizing Crohn’s Disease von Zulqarnain, Mir, Deepak, Parakkal, Yarur, Andres J.

Volltext Volltext Volltext

Reporting of Thromboembolic Events with JAK Inhibitors: Analysis of the FAERS Database 2010–2019 von Setyawan, Juliana, Azimi, Nassir, Strand, Vibeke, Yarur, Andres, Fridman, Moshe

Volltext Volltext Volltext

Predictors of Aggressive Inflammatory Bowel Disease von Yarur, Andres J., Strobel, Sebastian G., Deshpande, Amar R., Abreu, Maria T.

Volltext Volltext

Endoscopic and histological features of mycophenolate mofetil colitis in patients after solid organ transplantation von Calmet, Fernando H., Yarur, Andres J., Pukazhendhi, Geetha, Ahmad, Jawad, Bhamidimarri, Kalyan R.

Volltext Volltext

Therapeutic drug monitoring in patients with inflammatory bowel disease von Yarur, Andres J, Abreu, Maria T, Deshpande, Amar R, Kerman, David H, Sussman, Daniel A

Volltext Volltext Volltext

Cross-sectional analysis of patient phone calls to an inflammatory bowel disease clinic von Corral, Juan E., Yarur, Andres J., Diaz, Liege, Simmons, Okeefe L., Sussman, Daniel A.

Volltext Volltext

Serum trough levels of infliximab are not associated with peripheral arthralgia activity in patients with inflammatory bowel disease von Sekhri, Shaina, Rao, Bharat, Mohananey, Akanksha, Beniwal-Patel, Poonam, Bruss, Alexandra, Stein, Daniel J, Yarur, Andres J

Volltext Volltext Volltext

Outcomes in patients with inflammatory bowel disease and acute gastrointestinal symptoms who test indeterminate for Clostridioides difficile von Johnson, Lauren K., Munoz-Price, Silvia, Patel, Poonam Beniwal, Patel, Amir, Stein, Daniel J., Yarur, Andres J.

Volltext Volltext Volltext

Inflammatory Cytokine Profile in Crohn’s Disease Non-Responders to Optimal Anti-Tumor Necrosis Factor Therapy von Yarur, Andres J., Jain, Anjali, Quintero, Maria A, Czul, Frank, Deshpande, Amar R., Kerman, David H., Abreu, Maria T.

Volltext Volltext Volltext

Association Between Vedolizumab Levels, Anti-vedolizumab Antibodies, and Endoscopic Healing Index in a Large Population of Patients with Inflammatory Bowel Diseases von Yarur, Andres J., Deepak, Parakkal, Vande Casteele, Niels, Battat, Robert, Jain, Anjali, Okada, Lauren, Osterman, Mark, Regueiro, Miguel

Volltext Volltext Volltext

The Economic Burden of Thromboembolic Events Among Patients with Immune-Mediated Diseases von Setyawan, Juliana, Billmyer, Emma, Mu, Fan, Yarur, Andres, Zichlin, Miriam L., Yang, Hongbo, Downes, Nathaniel, Azimi, Nassir, Strand, Vibeke

Volltext Volltext Volltext

Risk of Thromboembolic Events and Associated Healthcare Costs in Patients with Inflammatory Bowel Disease von Setyawan, Juliana, Mu, Fan, Zichlin, Miriam L., Billmyer, Emma, Downes, Nathaniel, Yang, Hongbo, Azimi, Nassir, Strand, Vibeke, Yarur, Andres

Volltext Volltext Volltext

Vedolizumab as Induction and Maintenance for Inflammatory Bowel Disease: 12-month Effectiveness and Safety von Christensen, Britt, Colman, Ruben J, Micic, Dejan, Gibson, Peter R, Goeppinger, Sarah R, Yarur, Andres, Weber, Christopher R, Cohen, Russell D, Rubin, David T

Volltext Volltext Volltext

Clinical Response and Complications are not Associated with Drug Levels in Patients with Severe Ulcerative Colitis on IV Cyclosporine Induction Therapy von Patel, Parita, Yarur, Andres, Dalal, Sushila, Sakuraba, Atsuhi, Rubin, David T, Hanauer, Stephen B, Hanan, Ira, Raffals, Laura H, Cohen, Russell D, Pekow, Joel

Volltext Volltext Volltext

Effective use of Calcineurin Inhibitors with Vedolizumab in Refractory Inflammatory Bowel Disease von Christensen, Britt, Gibson, Peter, Micic, Dejan, Colman, Ruben J, Goeppinger, Sarah R, Kassim, Olufemmi, Yarur, Andres, Weber, Christopher R, Cohen, Russell D, Rubin, David T

Volltext Volltext Volltext

Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design von Tyler, Christopher J, Guzman, Mauricio, Lundborg, Luke R, Yeasmin, Shaila, Perez-Jeldres, Tamara, Yarur, Andres, Behm, Brian, Dulai, Parambir S, Patel, Derek, Bamias, Giorgos, Rivera-Nieves, Jesús

Volltext Volltext Volltext

Vedolizumab Concentrations Are Associated with Long-Term Endoscopic Remission in Patients with Inflammatory Bowel Diseases von Yarur, Andres J., Bruss, Alexandra, Naik, Snehal, Beniwal-Patel, Poonam, Fox, Caroline, Jain, Anjali, Berens, Brandon, Patel, Amir, Ungaro, Ryan, Bahur, Bayda, Dubinsky, Marla, Stein, Daniel J.

Volltext Volltext Volltext

Vedolizumab Serum Trough Concentrations and Response to Dose Escalation in Inflammatory Bowel Disease von Vaughn, Byron P., Yarur, Andres J., Graziano, Elliot, Campbell, James P., Bhattacharya, Abhik, Lee, Jennifer Y., Gheysens, Katherine, Papamichael, Konstantinos, Osterman, Mark T., Cheifetz, Adam S., Cross, Raymond K.

Volltext Volltext Volltext

Vedolizumab in patients with concurrent primary sclerosing cholangitis and inflammatory bowel disease does not improve liver biochemistry but is safe and effective for the bowel di... von Christensen, Britt, Micic, Dejan, Gibson, Peter R., Yarur, Andres, Bellaguarda, Emanuelle, Corsello, Paul, Gaetano, John N., Kinnucan, Jami, Rao, Vijaya L., Reddy, Shilpa, Singh, Samrath, Pekow, Joel, Rubin, David T.

Volltext Volltext Volltext

Targeting Cytokine Signaling and Lymphocyte Traffic via Small Molecules in Inflammatory Bowel Disease: JAK Inhibitors and S1PR Agonists von Pérez-Jeldres, Tamara, Tyler, Christopher J., Boyer, Joshua D., Karuppuchamy, Thangaraj, Yarur, Andrés, Giles, Daniel A., Yeasmin, Shaila, Lundborg, Luke, Sandborn, William J., Patel, Derek R., Rivera-Nieves, Jesús

Volltext Volltext Volltext